Dexmecamylamine

Generic Name: Dexmecamylamine

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₂₁N

CAS Number: 107538-05-6

Unique Ingredient Identifier: 5Y1141YI4U

Background: Dexmecamylamine has been used in trials studying the basic science and treatment of Patients, Depression, Drug Abuse, Pharmacokinetics, and Renal Impairment, among others.

Clinical Trials

Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Phase 2

Conditions: Palmar Hyperhidrosis
Hyperhidrosis

Interventions: Drug: Dexmecamylamine HCl
Other: Placebo

First Posted Date: 2020-02-11

Last Posted Date: 2021-07-22

Lead Sponsor: Atacama Therapeutics

Target Recruit Count: 75

Registration Number: NCT04263623

Locations: 🇺🇸
Site 01, Norfolk, Virginia, United States

Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Phase 2

Completed

Conditions: Palmar Hyperhidrosis

Interventions: Drug: Dexmecamylamine HCl
Other: Placebo

First Posted Date: 2018-01-19

Last Posted Date: 2019-11-21

Lead Sponsor: Atacama Therapeutics

Target Recruit Count: 60

Registration Number: NCT03404570

Locations: 🇺🇸
Site 03, Saint Louis, Missouri, United States
🇺🇸
Site 01, Norfolk, Virginia, United States
🇺🇸
Site 02, San Diego, California, United States

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

Phase 2

Completed

Conditions: Overactive Bladder

Interventions: Drug: dexmecamylamine
Drug: Placebo

First Posted Date: 2013-06-04

Last Posted Date: 2015-06-03

Lead Sponsor: Targacept Inc.

Target Recruit Count: 1635

Registration Number: NCT01868516

Locations: 🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States
🇺🇸
Westside Family Medical Center, PC, Kalamazoo, Michigan, United States
🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States

and more 107 locations

Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214

Phase 1

Withdrawn

Conditions: Drug Abuse
Healthy

Interventions: Drug: TC-5214
Drug: TC-5214 Placebo
Drug: Ketamine
Drug: Phentermine

First Posted Date: 2011-12-26

Last Posted Date: 2012-03-22

Lead Sponsor: AstraZeneca

Registration Number: NCT01500018

Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: TC-5214

First Posted Date: 2011-10-25

Last Posted Date: 2012-01-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT01458899

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

Phase 1

Terminated

Conditions: Chronic Hypertension

Interventions: Drug: TC-5214

First Posted Date: 2011-07-27

Last Posted Date: 2012-10-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 80

Registration Number: NCT01403922

Locations: 🇬🇧
Research Site, London, United Kingdom

A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TC-5214
Drug: Placebo

First Posted Date: 2011-07-13

Last Posted Date: 2011-11-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 48

Registration Number: NCT01392820

Locations: 🇯🇵
Research Site, Fukuoka, Japan

Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart

Phase 1

Terminated

Conditions: Healthy Male

Interventions: Other: Placebo comparator
Drug: TC-5214
Other: Moxifloxacin placebo comparator
Drug: Moxifloxacin

First Posted Date: 2011-05-25

Last Posted Date: 2012-12-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT01359618

Locations: 🇬🇧
Research Site, London, United Kingdom

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

Phase 2

Terminated

Conditions: Major Depressive Disorder

Interventions: Drug: TC-5214
Drug: Duloxetine
Drug: Placebo

First Posted Date: 2011-02-02

Last Posted Date: 2012-11-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 145

Registration Number: NCT01288079

Locations: 🇯🇵
Research Site, Kumamoto, Japan

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

Phase 1

Completed

Conditions: Healthy Volunteers
Patients
Pharmacokinetics
Renal Impairment

First Posted Date: 2010-11-15

Last Posted Date: 2014-03-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT01240967

Locations: 🇺🇸
Research site, Minneapolis, Minnesota, United States
🇺🇸
Research Site, Orlando, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy